drug

AL-108

as of 2026-07-01
Add to landscapeMonitor thisCompare thisAsk about this
at a glance
small molecule
Pre-approval / investigational in the US
Developed by University of California Riverside at C.I. Trials, Inc.-Inland Empire
1 trials in the graph
Synthesized from structured facts only — each point cited above.

Mechanism & identity

Modality
small molecule

Indications

Investigational (via trials)
SchizophreniaSchizophrenia

Trials

1
A Multicenter Study of NAP (AL-108) in Schizophrenia
NCT00505765Phase 2Completed

KOLs & investigators

1
Daniel C. Javitt, MD, PhDKOL score 8

Facts & assertions

0 sourced
No assertions recorded for this entity.
relationships
The graph out of here
developer
University of California Riverside at C.I. Trials, Inc.-Inland Empire
company
trial
A Multicenter Study of NAP (AL-108) in Schizophrenia
PHASE2
trial
indication
Schizophrenia
indication
Schizophrenia
indication
KOL
Daniel C. Javitt, MD, PhD
KOL score 8
person